SCHEMBL7907419

SCHEMBL7907419

COc1ccc2c(c1)c(C)c(CC(=O)O)n2C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C2 P52895 8/20 0.51
AKR1C3 P42330 7/20 0.51
AR P10275 2/20 0.51
AKR1C4 P17516 2/20 0.51
PTGS1 P23219 2/20 0.51
AKR1C1 Q04828 2/20 0.51
LMNA P02545 4/20 0.50
CYP1A2 P05177 4/20 0.50
CYP2C9 P11712 4/20 0.50
TSHR P16473 3/20 0.50
HIF1A Q16665 3/20 0.50
NPSR1 Q6W5P4 3/20 0.50
NFKB1 P19838 2/20 0.50
CYP2D6 P10635 2/20 0.50
PLA2G1B P04054 1/20 0.50
PLA2G2A P14555 1/20 0.50
MAPT P10636 5/20 0.48
PMP22 Q01453 3/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18271503 0.81 PLA2G2A (0.56) AKR1C2AKR1C3ARAKR1C4PTGS1
SCHEMBL8649350 0.81 AKR1C2 (0.67) AKR1C2AKR1C3ARAKR1C4PTGS1
SCHEMBL8367147 0.80 AKR1C2 (0.58) AKR1C2AKR1C3ARAKR1C4PTGS1
SCHEMBL9956776 0.78 KDM4E (0.52) TSHRNPSR1MAPTMEN1KMT2A
SCHEMBL8532819 0.77 ADRB2 (0.56) AKR1C2AKR1C3ARAKR1C4PTGS1
SCHEMBL8366206 0.77 KDM4E (0.55) AKR1C2AKR1C3AKR1C4PTGS1LMNA
SCHEMBL21095824 0.77 MAPT (0.46) AKR1C2AKR1C3ARAKR1C4PTGS1
SCHEMBL9959992 0.74 MAPT (0.49) CYP1A2NPSR1CYP2D6MAPTMEN1
SCHEMBL21096050 0.74 AKR1C3 (0.65) AKR1C2AKR1C3ARAKR1C4PTGS1
SCHEMBL12926010 0.74 MAPT (0.59) CYP1A2NPSR1CYP2D6MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1068338-A2 ENHANCED PRODRUG ACTIVATION Oxford Biomedica (UK) Limited (GB) 2001-01-17 EP disclosed
EP-0988057-A1 DRUG TARGETING Theramark Limited (GB) 2000-03-29 EP disclosed
WO-1999045127-A2 ENHANCED PRODRUG ACTIVATION OXFORD BIOMEDICA (UK) LIMITED (GB) 1999-09-10 WO disclosed
WO-1998035701-A1 DRUG TARGETING THERAMARK LIMITED (GB) 1998-08-20 WO disclosed